School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, People's Republic of China.
Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, Southern Medical University, Guangzhou 510515, People's Republic of China.
Int J Nanomedicine. 2020 Mar 25;15:2059-2070. doi: 10.2147/IJN.S240449. eCollection 2020.
Ferulic acid (FA) is a natural compound which is used to treat insomnia. However, its use is limited because of its poor oral bioavailability caused by extremely rapid elimination. The current study aimed to develop a self-microemulsifying drug delivery system (SMEDDS) to improve the oral delivery of FA and to enhance its hypnotic efficacy.
FA-SMEDDS was prepared, and its morphology and storage stability were characterized. The formulation was also subjected to pharmacokinetic and tissue distribution studies in rats. The hypnotic efficacy of FA-SMEDDS was evaluated in -chlorophenylalanine-induced insomnia mice.
FA-loaded SMEDDS exhibited a small droplet size (15.24 nm) and good stability. Oral administration of FA-SMEDDS yielded relative bioavailability of 185.96%. In the kidney, SMEDDS decreased the distribution percentage of FA from 76.1% to 59.4% and significantly reduced its metabolic conversion, indicating a reduction in renal elimination. Interestingly, FA-SMEDDS showed a higher distribution in the brain and enhanced serotonin levels in the brain, which extended the sleep time by 2-fold in insomnia mice.
This is the first study to show that FA-loaded SMEDDS decreased renal elimination, enhanced oral bioavailability, increased brain distribution, and improved hypnotic efficacy. Thus, we have demonstrated that SMEDDS is a promising carrier which can be employed to improve the oral delivery of FA and facilitate product development for the therapy of insomnia.
阿魏酸(FA)是一种天然化合物,用于治疗失眠。但其口服生物利用度极差,导致药物迅速消除,限制了其应用。本研究旨在开发自微乳给药系统(SMEDDS)以改善 FA 的口服递送并增强其催眠功效。
制备 FA-SMEDDS 并对其形态和储存稳定性进行了表征。还对 FA-SMEDDS 在大鼠中的药代动力学和组织分布进行了研究。通过 - 氯苯丙氨酸诱导的失眠小鼠评估了 FA-SMEDDS 的催眠功效。
载 FA 的 SMEDDS 表现出较小的粒径(15.24nm)和良好的稳定性。FA-SMEDDS 口服给药的相对生物利用度为 185.96%。在肾脏中,SMEDDS 将 FA 的分布百分比从 76.1%降低至 59.4%,并显著减少其代谢转化,表明肾脏消除减少。有趣的是,FA-SMEDDS 在大脑中的分布更高,并增加了大脑中的 5-羟色胺水平,使失眠小鼠的睡眠时间延长了 2 倍。
这是第一项表明载 FA 的 SMEDDS 可减少肾脏消除、提高口服生物利用度、增加脑分布并改善催眠功效的研究。因此,我们证明了 SMEDDS 是一种有前途的载体,可用于改善 FA 的口服递送并促进治疗失眠症的产品开发。